StockData
First Tracks Biotherapeutics, Inc. logo

First Tracks Biotherapeutics, Inc. (TRAX) stock

TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$43.57−2.99 (-6.42%)

Close on Nov 17, 2026Market cap $1.56BP/E –Yield –

Earnings

First Tracks Biotherapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.88
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of First Tracks Biotherapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 3, 2026after the close––-$0.88Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026after the close––-$0.95Release
Q1 FY2026ended Mar 31, 2026May 14, 2026after the close–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

First Tracks Biotherapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When First Tracks Biotherapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases First Tracks Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?